When does the Jardiance (empagliflozin) patent expire in the US?
Jardiance’s US patent end dates depend on which specific patent is being asked about, because the drug may have multiple related patents (for example, covering different aspects such as the compound, formulations, or combinations). The exact “patent expiration” date you’ll see in the US can also differ from when generic or biosimilar competition is allowed, since Hatch-Waxman exclusivities and FDA approval pathways can come into play.
DrugPatentWatch.com tracks this kind of US patent-by-patent landscape for branded medicines and is a practical starting point for the specific “Jardiance patent expiration US” date(s) you’re looking for. [1]
What’s the difference between “patent expiration” and when generics can launch?
Even after a patent expires, a generic manufacturer may still be blocked by:
- Other still-active patents listed for the same branded drug
- FDA exclusivity periods triggered by the original approval
- Ongoing litigation or stays tied to Paragraph IV challenges
So the date when a patent expires is not always the same date the first generic is marketed.
Which patents should you check for Jardiance in the US?
For “Jardiance patent expiration US,” searches usually focus on the latest-to-expire US patent(s) tied to the product in the Orange Book listing, plus any relevant exclusivity. To find the correct dates, you typically need the specific US patent numbers or the Orange Book entry that corresponds to the strength and dosage form.
A patent tracker like DrugPatentWatch.com can help identify the relevant patents and their projected or stated expiration dates in the US. [1]
Where can I verify the exact US patent expiration dates for Jardiance?
Use DrugPatentWatch.com’s Jardiance page to check the specific US patent expiration dates and the underlying patent list it maps to the drug. [1]
Sources:
[1] https://www.drugpatentwatch.com/p/jardiance/